tehbart schreef op 12 maart 2018 18:55:
Van hun site:
Kiadis Pharma intends to use the net proceeds of the Placing to:
? continue the Phase 3 international, randomized, controlled, multicentre clinical trial for ATIR101
in the United States, Canada and Europe;
? generate additional manufacturing capacity at vendors and to refurbish, equip and staff its leased
manufacturing facility;
? further prepare the Company for commercialization by investing into a commercial organization,
market access preparation and reimbursement discussions;
? support further production process optimization of ATIR;
? expand the organization to accommodate the increased number of activities;
? start a further clinical trial to assess the benefit of ATIR101 in conjunction with another T-cell
depleted hematopoietic stem cell transplantation (HSCT) protocol or with a cyclophosphamide-
based haplo transplantation protocol;
? apply funds for debt repayment, capital expenditures, general and administrative expenses,
general corporate purposes in line with Kiadis Pharma's strategy and other working capital needs;
and
? finance potential opportunities to broaden and diversify the research and development portfolios
(e.g. through in-licensing or acquiring programs and companies with synergistic or complementary
technologies, products and/or product candidates).